Forget about those Internet companies. Instead, take a look at the skyrocketing stock price of Celera Genomics, a biotech firm in Rockville, Md., that is racing to sequence the human genome a year or two before the government-funded international effort does (SN: 5/23/98, p. 334). Celera’s stock received its latest boost Jan. 10 when the company announced that it has sequenced 90 percent of the human genome and claimed it has found about 97 percent of all human genes.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.